Search clinical trials for: 111Indium-bevacizumab

Total 2461 results

NSABP Foundation Inc
Hoffmann-La Roche; Genentech, Inc.; International Drug Development Institute

Terminated

Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon

Colorectal Neoplasms

United States
Massachusetts General Hospital
National Cancer Institute (NCI); Genentech, Inc.

Unknown

Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Gruppo Oncologico del Nord-Ovest

Unknown

Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC (TRIBE2)

Metastatic Colorectal Cancer

Italy
The University of Hong Kong

Unknown

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

NSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB

Hong Kong
National Taiwan University Hospital

Unknown

Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC

Stage III Esophageal Squamous Cell Carcinoma

Taiwan
Centre Hospitalier Intercommunal Creteil
Groupe Français de Pneumo-Cancérologie

Terminated

Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases (METAL2)

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Cerebral Metastases | Adenocarcinoma of Lung Metastatic to Brain

France
University of California, Davis
National Cancer Institute (NCI); NovoCure Ltd.

Withdrawn

NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

Recurrent Adult Brain Neoplasm | Adult Brain Glioblastoma

United States
Pfizer

Completed

Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT)

Renal Cell Carcinoma

France, Belgium, Hungary, Taiwan, United States, Australia, Spain, Hong Kong, Malaysia, Serbia, Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Germany, India, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation and more
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma

United States
M.D. Anderson Cancer Center
Jazz Pharmaceuticals

Recruiting

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Ovarian Cancer

United States
University of California, Irvine

Active, not recruiting

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

Breast Carcinoma

United States
Dorte Nielsen
Danish Cancer Society

Withdrawn

FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer (IMMUNOX)

Metastatic Colorectal Cancer

Denmark
Taiho Oncology, Inc.

Completed

A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.

Advanced Gastrointestinal Tumors

United States
Maturi, Raj K., M.D., P.C.

Completed

Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD

Age-Related Macular Degeneration

United States
Vejle Hospital

Completed

Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations (GOC-B-P)

Cholangiocarcinoma

Denmark
Amgen
Genentech, Inc.

Completed

A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab

Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center

Completed

Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

Peritoneal Cancer

United States
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Triple Negative Breast Cancer

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Triple Negative Breast Cancer
ImmunityBio, Inc.

Unknown

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Squamous Cell Carcinoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer

United States
National Cancer Institute (NCI)

Completed

A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Terminated

Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Recurrent Uterine Corpus Sarcoma | Uterine Corpus Leiomyosarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma

United States
Sun Yat-sen University

Recruiting

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

Recurrent Cervical Cancer | Stage IVB Cervical Cancer | Persistent Cervical Cancer

China
Hunan Province Tumor Hospital

Recruiting

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC (CONFIRM)

Non-small Cell Lung Cancer

China
CCTU- Cancer Theme
Microbiotica Ltd

Recruiting

Microbiome Immunotherapy Toxicity and Response Evaluation

Melanoma | Lung Cancer | Renal Cancer

United Kingdom
Sun Yat-sen University

Recruiting

Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC (NIBCUN)

Lung Cancer Stage III

China
Qingdao Central Hospital

Recruiting

Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab

Pulmonary Fibrosis

China
Gustave Roussy, Cancer Campus, Grand Paris

Active, not recruiting

Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer (PEMBOV)

Ovarian Cancer

France
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

IBI188 Combination Therapy in Solid Tumors

Osteosarcoma | Lung Adenocarcinoma | Solid Tumors

China
Federation Francophone de Cancerologie Digestive

Active, not recruiting

Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO)

Metastatic Colorectal Cancer | MSI

France
Jiangsu HengRui Medicine Co., Ltd.

Completed

To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC

Non-small Cell Lung Cancer(NSCLC)

China
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Austria, France, Hungary, United Kingdom, Italy, Germany, Spain
Tracon Pharmaceuticals Inc.

No longer available

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

Solid Tumors

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca; Genentech, Inc.

Completed

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Eli Lilly and Company; Genentech, Inc.

Terminated

Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Bayer

Completed

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Terminated

Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors

Pancreatic Cancer

United States
Seoul National University Hospital
Boryung Pharmaceutical Co., Ltd

Active, not recruiting

High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy (SELENIUM)

Ovarian Cancer | Fallopian Tube Cancer | Recurrent Ovarian Carcinoma | Chemotherapy-induced Peripheral Neuropathy | Primary Peritoneal Carcinoma

Korea, Republic of
William Sikov MD
Yale University

Completed

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

Breast Cancer

United States
Cliniques universitaires Saint-Luc- Université...
Grand Hôpital de Charleroi

Completed

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI. (BEV-ONCO2012)

Metastatic Colorectal Cancer

Belgium
NYU Langone Health
MOUNT SINAI HOSPITAL

Withdrawn

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Glioma | Glioblastoma

United States
EPS Corporation

Completed

Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (ATOM)

Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer

Japan
Dana-Farber Cancer Institute
Massachusetts General Hospital; Genentech, Inc.; Brigham and Women's Hospital

Completed

Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

Stomach Cancer | Esophageal Cancer

United States
Stanford University
Eli Lilly and Company; Genentech, Inc.

Completed

Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
Memorial Sloan Kettering Cancer Center

Completed

Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment

Lung Cancer

United States
Aktion Bronchialkarzinom e.V.
Roche Pharma AG

Completed

Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab (INNOVATIONS)

Carcinoma, Non-Small-Cell Lung

Germany
Shahid Beheshti University of Medical Sciences
Labbafinejad Medical Center

Unknown

Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion (BRVO)

Branch Retinal Vein Occlusion

Iran, Islamic Republic of
Holy Stone Healthcare Co., Ltd

Not yet recruiting

Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
University Health Network, Toronto
GlaxoSmithKline

Recruiting

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Serous Cancer | High Grade Endometrioid Cancer

Canada

Search clinical trials for: 111Indium-bevacizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations